In this cohort, serum adiponectin was only able to distinguish NAFL vs. NASH when NAFLD patients homozygous for PNPLA3 wild-type allele c.444C were considered, even though with a suboptimal performance (AUROC = 0.63; p < 0.05) (Figure 3B). This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.